Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Advances in New Stent Designs without a Permanent Polymer May Solve Polymer-related Complications
Author(s):
Chourmouzios A Arampatzi
,
Raul Moreno
,
Giuseppe Sangiorgi
Added:
3 years ago
Article
Author(s):
Giuseppe Sangiorgi
,
Fabrizio Clementi
,
Clarissa Cola
Added:
3 years ago
Several independent lines of clinical evidence have shown that critical stenoses cause only a fraction of ACS. Rather, ruptures of a thin fibrous cap covering a large lipid-rich necrotic or superficial intimal erosion frequently trigger acute coronary thromboses at sites of non-critical narrowing of coronary arteries. This shift in thinking has fostered the notion of the so-called 'vulnerable' or…
View more
Author(s):
Meril Life Sciences
Added:
3 years ago
The first-generation drug-eluting stents (DES) initially demonstrated good promise in terms of reducing the degree of restenosis. They succeeded in arresting the neo-intimal proliferation, which was the bane of coronary stents.1 Over a period of time, however, the polymeric degradation by-products failed to bring about an essential component of the healing process: endothelialisation. Failure of…
View more
Author(s):
Jun Hua Chong
,
Arjun K Ghosh
Added:
3 years ago
Cardiovascular disease is the leading cause of morbidity and mortality worldwide.1 The WHO estimates that 17 million people die each year of cardiovascular disease, about 30% of all deaths.2 Cancer is the second leading cause of death globally and is associated with 9 million deaths each year.3 According to the WHO, the incidence of cancer is expected to rise by about 70% over the next 20 years.4…
View more
Author(s):
Adnan Kastrati
Added:
3 years ago
Compared with conventional bare-metal stents (BMS), the introduction of drug-eluting stents (DES) has resulted in a substantial reduction in the incidence of in-stent restenosis.1 DES systems eluting either sirolimus2 or paclitaxel3 from a polymer stent coating have been shown in randomised trials to effectively inhibit the process of neointimal proliferation, resulting in restenosis reduction.
…
View more
Author(s):
Benjamin Galper
,
Roxana Mehran
Added:
3 years ago
Acute coronary syndromes (ACS) result from unstable coronary artery plaques that rupture and can lead to coronary ischaemia, unstable angina and myocardial infarction. The treatment goals in ACS focus on reducing ischaemia, preventing further progression of thrombotic plaque by disturbing the milieu of thrombosis and platelet aggregation taking place within the coronary artery and, in the case of…
View more
Primary Angioplasty for Acute Myocardial Infarction and the Emerging Role of Renal Insufficiency
Author(s):
Giancarlo Marenzi
,
Antonio L Bartorelli
Added:
3 years ago
Article
Author(s):
Nicolaus Reifart
,
Mariann Gyöngyösi
,
Karl-Eugen Hauptmann
,
et al
Added:
3 years ago
Coronary stent implantation is one of the most important developments in the field of percutaneous coronary revascularisation after the introduction of balloon angioplasty in 1977.1 The treatment of coronary artery disease (CAD) using a bare-metal stent (BMS) is considered effective; however, restenosis occurs in 15–35% of all cases, requiring repeated treatment.2–4 To overcome the restenosis…
View more
Author(s):
Edwin Lee
,
Ajay J Kirtane
Added:
3 years ago
The outcomes of patients with ST-segment elevation myocardial infarction (STEMI) have improved in recent years with the more widespread adoption of definitive reperfusion therapies, including rapid recanalisation of the infarct-related artery with percutaneous coronary intervention (PCI). Nonetheless, despite the near universal restoration of normal epicardial flow following primary PCI for STEMI…
View more